Related Experiment Videos
Claudia Pasqualini1, Fanny Rialland2, Dominique Valteau-Couanet1
1Département de cancérologie de l'enfant et de l'adolescent, Gustave-Roussy.
New Perspectives In Immunotherapies For Pediatric Malignancies:
New therapeutic paradigms are needed to improve the survival of children and adolescents with high-risk malignancies, and to reduce the sequelae associated with treatment. Immunotherapies, targeting tumor cells and/or the immune system to enhance existing anti-tumor immunity or induce novel anti-tumor immune responses, are becoming increasingly successful in adult oncology. Based on the results obtained with anti-ganglioside2 antibodies in neuroblastoma, rituximab in mature B malignancies, immune checkpoint inhibitors in lymphoma and especially in Hodgkin lymphoma, blinatumomab and CAR-T CD19 cells for B-cell acute lymphoblastic leukemia, immunotherapy has demonstrated irrefutable benefits in pediatric patients. However, these results are currently limited to a minority of patients and histologies. Current and ongoing trials tend to focus on a single type of immunotherapy, but it is likely that combinations of immunotherapies with different mechanisms of action or combination with other classes of anti-cancer treatments will be additives or even synergistic. The development of this new class of drugs in the treatment of pediatric cancers has multiple challenges: to better evaluate the response to treatment, to define the optimal doses and schedules, to manage immuno-mediated toxicities, to identify its specific sequelae, and, finally, to better understand the strategies of immune evasion of pediatric cancers in order to develop efficient immunotherapies.
Insights
Immunotherapy shows promise for pediatric cancers, offering new hope for young patients. Further research is needed to overcome challenges and expand its use in treating high-risk malignancies.
Area of Science:
- Pediatric Oncology
- Cancer Immunotherapy
- Tumor Immunology
Background:
- Pediatric high-risk malignancies require novel therapeutic strategies to improve survival and reduce treatment-related side effects.
- Immunotherapy has shown significant success in adult oncology and is emerging as a valuable approach in pediatric cancer treatment.
Purpose of the Study:
- To review the current landscape and future perspectives of immunotherapies for pediatric malignancies.
- To highlight the successes, challenges, and potential of immunotherapy in treating cancers in children and adolescents.
Main Methods:
- Review of existing literature and clinical trial data on immunotherapies in pediatric oncology.
- Analysis of specific immunotherapeutic agents and their efficacy in various pediatric cancers (e.g., neuroblastoma, B-cell acute lymphoblastic leukemia, lymphomas).
Main Results:
- Immunotherapies like anti-GD2 antibodies, rituximab, immune checkpoint inhibitors, blinatumomab, and CAR-T CD19 cells have demonstrated benefits in specific pediatric malignancies.
- Current successes are limited to a subset of patients and cancer types, indicating a need for broader application.
- Combinatorial approaches involving different immunotherapies or combination with other anti-cancer treatments may offer synergistic effects.
Conclusions:
- Immunotherapy holds significant potential for treating pediatric cancers, but challenges remain in optimizing treatment response evaluation, dosing, toxicity management, and understanding immune evasion strategies.
- Future research should focus on combination therapies and addressing the unique challenges of pediatric cancer immunotherapy to improve outcomes for all young patients.